SCHEMBL6936085

SCHEMBL6936085

O=C(O)C[n+]1csc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.57
KDM4E B2RXH2 9/20 0.57
MAPT P10636 7/20 0.57
HPGD P15428 7/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALOX12 P18054 1/20 0.47
LMNA P02545 2/20 0.44
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
POLB P06746 2/20 0.33
ALPG P10696 1/20 0.33
HTT P42858 1/20 0.33
AKR1B1 P15121 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2951033 0.98 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL8390275 0.98 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL8390272 0.97 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL8987983 0.91 ALDH1A1 (0.49) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL6935716 0.84 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL2954113 0.83 KMT2A (0.55) ALDH1A1KDM4EMAPTHPGDMEN1
Hydrochloric Acid SCHEMBL1520138 0.83 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL8385551 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL2954205 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTHPGDMEN1
Bromide SCHEMBL8385548 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2778262-B1 COPPER PLATING METHOD FOR THE MANUFACTURE OF SOLAR CELLS MACDERMID ENTHONE AMERICA LLC (US) 2019-05-08 EP claimed
CN-1142778-C Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts 2004-03-24 CN claimed
EP-0808163-B1 USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS ALTEON INC (US) 2003-07-23 EP claimed
US-6440749-B1 ADMINISTERING A THIAZOLE COMPOUND ALTEON. INC. 2002-08-27 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0615854-B1 Recording sheets containing cationic sulphur compounds XEROX CORP (US) 1997-06-04 EP claimed
US-11192908-B2 Octamolybdate compounds exhibiting bright emission NANOCO 2D MATERIALS LIMITED (GB) 2021-12-07 US disclosed
US-20200055884-A1 Octamolybdate Compounds Exhibiting Bright Emission NANOCO TECHNOLOGIES LIMITED (GB) 2020-02-20 US disclosed
EP-2778262-A1 Copper plating solutions and method of making and using such solutions Omg Electronic Chemicals LLC (US) 2014-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192908-B2 Octamolybdate compounds exhibiting bright emission KCNN4, PUF60, OCIAD1 ALDH1A1 2429/4885KDM4E 287/4885MAPT 55/4885
US-20200055884-A1 Octamolybdate Compounds Exhibiting Bright Emission KCNN4, PUF60, OCIAD1 ALDH1A1 2429/4885KDM4E 287/4885MAPT 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.